Researchers analyzed data from 1,250 patients with early rheumatoid arthritis to see how different treatment types worked across various joint involvement patterns. The study looked at two main groups: those with primarily hand involvement and those with polyarticular (multiple) involvement. They compared the effectiveness of conventional synthetic DMARDs and biologic DMARDs.
The findings showed a link between where the disease was located and how patients responded to treatment. Patients in the hand-focused group saw significantly better scores in disease activity after 48 weeks. In contrast, those with polyarticular involvement showed less improvement. However, both types of medication were found to be similarly effective within their specific groups.
It is important to note that this study shows a link between joint location and outcomes rather than proving one drug is better than another overall. Additionally, the data did not show a significant link between certain antibodies and treatment success. Because this was an analysis of existing data, it may not change daily clinical practice immediately, but it highlights how individual symptoms might vary.
